LGT Capital Partners LTD. Has $130.26 Million Position in Stryker Co. (NYSE:SYK)

LGT Capital Partners LTD. increased its stake in Stryker Co. (NYSE:SYK) by 24.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 434,997 shares of the medical technology company’s stock after acquiring an additional 85,240 shares during the period. Stryker makes up approximately 3.9% of LGT Capital Partners LTD.’s investment portfolio, making the stock its 7th biggest position. LGT Capital Partners LTD.’s holdings in Stryker were worth $130,264,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in SYK. Vanguard Group Inc. boosted its holdings in shares of Stryker by 0.5% in the third quarter. Vanguard Group Inc. now owns 30,665,520 shares of the medical technology company’s stock valued at $8,379,967,000 after purchasing an additional 143,631 shares during the period. BlackRock Inc. lifted its holdings in shares of Stryker by 4.8% in the 2nd quarter. BlackRock Inc. now owns 25,862,485 shares of the medical technology company’s stock worth $7,890,386,000 after buying an additional 1,188,957 shares during the period. State Street Corp grew its position in shares of Stryker by 2.4% during the 2nd quarter. State Street Corp now owns 14,393,817 shares of the medical technology company’s stock worth $4,402,083,000 after buying an additional 340,114 shares in the last quarter. Morgan Stanley increased its stake in shares of Stryker by 21.7% during the fourth quarter. Morgan Stanley now owns 5,978,782 shares of the medical technology company’s stock valued at $1,461,753,000 after buying an additional 1,066,751 shares during the period. Finally, FMR LLC lifted its stake in Stryker by 2.5% in the third quarter. FMR LLC now owns 5,972,582 shares of the medical technology company’s stock worth $1,632,127,000 after acquiring an additional 144,208 shares during the period. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 201,146 shares of the stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $342.90, for a total value of $68,972,963.40. Following the completion of the sale, the director now owns 3,755,128 shares of the company’s stock, valued at $1,287,633,391.20. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, Director Ronda E. Stryker sold 201,146 shares of Stryker stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $342.90, for a total transaction of $68,972,963.40. Following the sale, the director now owns 3,755,128 shares of the company’s stock, valued at approximately $1,287,633,391.20. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Allan C. Golston sold 3,273 shares of the firm’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $341.00, for a total value of $1,116,093.00. Following the sale, the director now directly owns 14,242 shares of the company’s stock, valued at approximately $4,856,522. The disclosure for this sale can be found here. In the last ninety days, insiders sold 212,109 shares of company stock valued at $72,845,768. 5.90% of the stock is owned by insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on SYK. Morgan Stanley upped their price objective on Stryker from $300.00 to $320.00 and gave the stock an “equal weight” rating in a research note on Monday, December 4th. Truist Financial boosted their price target on Stryker from $330.00 to $345.00 and gave the stock a “hold” rating in a research note on Wednesday, January 31st. Roth Mkm increased their price objective on shares of Stryker from $345.00 to $348.00 and gave the company a “buy” rating in a research report on Wednesday, January 31st. Canaccord Genuity Group upgraded shares of Stryker from a “hold” rating to a “buy” rating and set a $360.00 price target on the stock in a research note on Wednesday, January 31st. Finally, Citigroup increased their price objective on Stryker from $340.00 to $362.00 and gave the company a “buy” rating in a report on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $331.52.

Stryker Trading Down 0.2 %

Shares of NYSE:SYK opened at $357.87 on Friday. The firm has a market capitalization of $136.16 billion, a price-to-earnings ratio of 43.38, a price-to-earnings-growth ratio of 2.92 and a beta of 0.89. The business’s 50 day moving average price is $343.42 and its 200-day moving average price is $305.60. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.58 and a quick ratio of 0.97. Stryker Co. has a 1 year low of $249.98 and a 1 year high of $361.41.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, topping the consensus estimate of $3.27 by $0.19. Stryker had a net margin of 15.44% and a return on equity of 22.99%. The firm had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. During the same quarter in the prior year, the firm earned $3.00 EPS. The company’s revenue for the quarter was up 11.8% on a year-over-year basis. On average, equities research analysts forecast that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be given a dividend of $0.80 per share. This represents a $3.20 annualized dividend and a dividend yield of 0.89%. The ex-dividend date is Wednesday, March 27th. Stryker’s payout ratio is 38.79%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.